<DOC>
	<DOC>NCT02677220</DOC>
	<brief_summary>The aim of this study is to investigate the clinical benefit for patients implanted with the Nucleus® CI532 cochlear implant. The Nucleus® CI532 has a pre-curved, perimodiolar array, the EA32, which is introduced into the cochlea through a straightening sheath.</brief_summary>
	<brief_title>Implantation With the Nucleus CI532 Cochlear Implant in Adults</brief_title>
	<detailed_description />
	<mesh_term>Hearing Loss</mesh_term>
	<criteria>Meet current cochlear implant criteria at the implanting center 18 years or older with bilateral sensorineural hearing loss Limited benefit from appropriate binaural hearing aids Moderate to profound hearing loss in the low frequencies and profound hearing loss in the mid to high frequencies Preoperative unaided threshold between 40 and 65 dB HL, inclusively, at 250 Hertz (Hz) and 500 Hz in the ear to be implanted Fluent speaker in the language used to assess clinical performance Evidence of hearing loss prior to age 5 Sensorineural severe to profound hearing loss greater than 20 years at and above 2000Hz Simultaneous bilateral implantation prior to the study Medical or psychological conditions that contraindicate undergoing general anesthesia or surgery Cochlear anomaly that might prevent complete insertion of the electrode array Hearing impairment due to lesion or neuropathy of the acoustic nerve, VIII nerve, or central auditory pathway Active middle ear infection Tympanic membrane perforation Unrealistic expectations Unwillingness or inability co comply with all investigational requirements Patients with existing cerebral shunts or drains Recurrent episodes of bacterial meningitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>